US Patent

US8648098 — Pirfenidone therapy and inducers of cytochrome P450

Method of Use · Assigned to Intermune Inc · Expires 2030-01-08 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for avoiding adverse interactions between pirfenidone and substances that induce cytochrome P450, such as smoking.

USPTO Abstract

The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2051 —
U-1611 —
U-2052 —
U-2052 —

Patent Metadata

Patent number
US8648098
Jurisdiction
US
Classification
Method of Use
Expires
2030-01-08
Drug substance claim
No
Drug product claim
No
Assignee
Intermune Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.